脂肪移植联合脂肪干细胞在美容性隆乳中的应用:临床、组织学与仪器评估
本研究比较脂肪移植联合脂肪干细胞(FG-e-ASCs)与单纯脂肪移植(FG-ne-ASCs)在乳房发育不良患者美容性隆乳中的安全性和有效性。FG-e-ASCs组46例,对照组30例。结果显示FG-e-ASCs组3年后轮廓恢复和三维体积维持率为58%,对照组为29%;FG-e-ASCs组67.4%的患者在36个月时轮廓恢复且三维体积增加10.3 mm,对照组仅20.0%。FG-e-ASCs组体积持久性显著高于对照组(P < 0.0001)。结论认为FG-e-ASCs在本系列病例中安全有效。
要点
- FG-e-ASCs隆乳3年后体积维持率58%,显著高于单纯脂肪移植的29%。
- FG-e-ASCs组67.4%患者36个月时轮廓恢复且体积增加10.3 mm。
- FG-e-ASCs用于美容性隆乳在本系列中安全有效。
核心结论
- FG-e-ASCs在美容性隆乳中安全有效,体积维持率优于单纯脂肪移植。
研究设计与样本
- 研究纳入46例乳房发育不良患者接受FG-e-ASCs治疗,对照组30例接受FG-ne-ASCs治疗。
- 术前评估包括临床评估、 photographic assessment、软组织磁共振成像、超声和乳腺X线摄影。
- 术后随访在1、3、7、12、24、48周及之后每年进行。
主要发现
- FG-e-ASCs组3年后轮廓恢复和三维体积维持率为58%,对照组为29%。
- FG-e-ASCs组67.4%(n=31)的患者在36个月时观察到乳房轮廓恢复且三维体积增加10.3 mm,对照组仅20.0%(n=6)。
- FG-e-ASCs组体积持久性高于对照组(P < 0.0001)。
临床怎么用
- 对于寻求美容性隆乳的乳房发育不良患者,可考虑使用FG-e-ASCs以改善远期体积维持。
- 术后需按计划进行临床、影像学随访以评估体积维持和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fat graft enhanced with adipose-derived stem cells (FG-e-ASCs) has been utilized in outcomes of radiotherapy after mastectomy, breast soft tissue defects, ulcers, and loss of substance. The authors present their experience utilizing FG-e-ASCs in breast augmentation. OBJECTIVES: The aim of this study was to evaluate the safety and efficacy of a study group (SG) regarding utilization of FG-e-ASCs in breast augmentation for aesthetic improvement, comparing the results with a control group (CG). METHODS: A total of 46 patients affected by breast hypoplasia were treated with FG-e-ASCs, comparing results with those of a CG (n = 30) treated with fat graft not enhanced with adipose-derived stem cells (FG-ne-ASCs). The preoperative evaluation included a complete clinical evaluation, a photographic assessment, magnetic resonance imaging of the soft tissue, ultrasound, and mammography. Postoperative follow-up took place at 1, 3, 7, 12, 24, and 48 weeks and then annually. RESULTS: The patients treated with FG-e-ASCs showed 58% maintenance of the contour restoring and of 3-dimensional (3D) volume after 3 years compared with the patients of the CG treated with FG-ne-ASCs, who showed 29% maintenance. In 67.4% (n = 31) of breast augmentations treated with FG-e-ASCs, we observed a restoration of the breast contour and an increase of 10.3 mm in the 3D volume after 36 months, which was observed in only 20.0% (n = 6) of patients in the CG treated with FG-ne-ASCs. Volumetric persistence in the SG was higher than that in the CG (P < 0.0001 SG vs CG). CONCLUSIONS: Utilization of FG-e-ASCs was safe and effective in this series of cases performed.
引用
- Gentile P, Kothari A, Casella D, et al. Fat Graft Enhanced With Adipose-Derived Stem Cells in Aesthetic Breast Augmentation: Clinical, Histological, and Instrumental Evaluation. Aesthet Surg J. 2020. PMID: 31637416. doi:10.1093/asj/sjz292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。